Dr. Pravin U. Dugel discusses a recent study showing that patients with neovascular AMD treated with a combination of Fovista (Ophthotec), an anti-platelet-derived growth factor (anti-PDGF) agent, and ranibizumab achieved a 62% relative visual benefit over anti-VEGF monotherapy. Dr. Dugel presented phase 2B study results at the 2012 Annual Scientific Meeting of the American Society of Retina Specialists (ASRS).

Financial Disclosure: Dr. Dugel receives consulting fees from Abbott Medical Optics, Alcon Laboratories, Allergan, Arctic Dx, Genentech, Macusight, Neovista, ORA, Regeneron Pharmaceuticals, and ThromboGenics.